This review aims to present the developments occurring in the field of artificial organs and particularly focuses on the presentation of developments in artificial kidneys.The challenges for biomedical engineering inv...This review aims to present the developments occurring in the field of artificial organs and particularly focuses on the presentation of developments in artificial kidneys.The challenges for biomedical engineering involved in overcoming the potential difficulties are showcased,as well as the importance of interdisciplinary collaboration in this marriage of medicine and technology.In this review,modern artificial kidneys and the research efforts trying to provide and promise artificial kidneys are presented.But what are the problems faced by each technology and to what extent is the effort enough to date?展开更多
目的评价微载体培养的永生化人肝细胞(immortalized human hepatocytes,IHH)对裸鼠急性肝衰竭(acute liver failure,ALF)的治疗作用。方法采用腹腔注射四氯化碳(CCl4)建立裸鼠ALF模型,将微载体培养的IHH注射于裸鼠腹腔内进行腹膜透析治...目的评价微载体培养的永生化人肝细胞(immortalized human hepatocytes,IHH)对裸鼠急性肝衰竭(acute liver failure,ALF)的治疗作用。方法采用腹腔注射四氯化碳(CCl4)建立裸鼠ALF模型,将微载体培养的IHH注射于裸鼠腹腔内进行腹膜透析治疗,并设未治疗组和空微载体治疗组,比较各组动物的肝功能损伤指标,肝组织病理和动物生存率。结果腹腔注射CCl4后24h,所有动物的转氨酶升高达正常值10倍以上,未治疗组和空微载体治疗组动物48h内全部死亡,肝组织检查发现肝细胞广泛坏死;而采用IHH微载体治疗组,48h的动物生存率为83.3%,持续14d后转为长期存活。存活的动物转氨酶降至正常水平,肝组织检查显示肝细胞坏死显著减少,免疫组织化学染色显示腹腔微载体上肝细胞仍存活,并表达人肝细胞特异蛋白α1-抗胰蛋白酶(α1-antitrypsin,α1-AT)。结论采用微载体培养的IHH腹腔透析治疗小鼠ALF是有效的,表明IHH适合作为生物人工肝的细胞材料。展开更多
文摘This review aims to present the developments occurring in the field of artificial organs and particularly focuses on the presentation of developments in artificial kidneys.The challenges for biomedical engineering involved in overcoming the potential difficulties are showcased,as well as the importance of interdisciplinary collaboration in this marriage of medicine and technology.In this review,modern artificial kidneys and the research efforts trying to provide and promise artificial kidneys are presented.But what are the problems faced by each technology and to what extent is the effort enough to date?
文摘目的评价微载体培养的永生化人肝细胞(immortalized human hepatocytes,IHH)对裸鼠急性肝衰竭(acute liver failure,ALF)的治疗作用。方法采用腹腔注射四氯化碳(CCl4)建立裸鼠ALF模型,将微载体培养的IHH注射于裸鼠腹腔内进行腹膜透析治疗,并设未治疗组和空微载体治疗组,比较各组动物的肝功能损伤指标,肝组织病理和动物生存率。结果腹腔注射CCl4后24h,所有动物的转氨酶升高达正常值10倍以上,未治疗组和空微载体治疗组动物48h内全部死亡,肝组织检查发现肝细胞广泛坏死;而采用IHH微载体治疗组,48h的动物生存率为83.3%,持续14d后转为长期存活。存活的动物转氨酶降至正常水平,肝组织检查显示肝细胞坏死显著减少,免疫组织化学染色显示腹腔微载体上肝细胞仍存活,并表达人肝细胞特异蛋白α1-抗胰蛋白酶(α1-antitrypsin,α1-AT)。结论采用微载体培养的IHH腹腔透析治疗小鼠ALF是有效的,表明IHH适合作为生物人工肝的细胞材料。
